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Abstract
Background: In epidemiologic studies, cancer stage is an important predictor of outcomes. However, cancer stage
is typically unavailable in medical insurance claims datasets, thus limiting the usefulness of such data for
epidemiologic studies. Therefore, we sought to develop an algorithm to predict cancer stage based on covariates
available from claims-based data.
Methods: We identified a cohort of 77,306 women age ≥ 66 years with stage I-IV breast cancer, using the
Surveillence Epidemiology and End Results (SEER)-Medicare database. We formulated an algorithm to predict
cancer stage using covariates (demographic, tumor, and treatment characteristics) obtained from claims. Logistic
regression models derived prediction equations in a training set, and equations’ test characteristics (sensitivity,
specificity, positive predictive value (PPV), and negative predictive value [NPV]) were calculated in a validation set.
Results: Of the entire sample of women diagnosed with invasive breast cancer, 51% had stage I; 26% stage II; 11%
stage III; and 4% stage IV disease. The equation predicting stage IV disease achieved sensitivity of 81%, specificity
89%, positive predictive value (PPV) 24%, and negative predictive value (NPV) 99%, while the equation
distinguishing stage I/II from stage III disease achieved sensitivity 83%, specificity 78%, PPV 98%, and NPV 31%.
Combined, the equations most accurately identified early stage disease and ascertained a sample in which 98% of
patients were stage I or II.
Conclusions: A claims-based algorithm was utilized to predict breast cancer stage, and was particularly successful
when used to identify early stage disease. These prediction equations may be applied in future studies of breast
cancer patients, substantially improving the utility of claims-based studies in this group. This method may similarly
be employed to develop algorithms permitting claims-based epidemiologic studies of patients with other cancers.
Background
Administrative medical insurance claims are an impor-
tant source of population-based data used in epidemio-
logic studies of various diseases. Specifically, in older
patients, national Medicare data have been useful for
the study of many conditions, including myocardial
infarction, heart failure, chronic kidney disease, Parkin-
son’s disease, and venous thromboembolism [1-5]. How-
ever, for studying cancer, the use of national Medicare
data has, to date, been limited. Medicare claims data are
clearly recognized as potentially a rich source for cancer
epidemiology and outcomes research, and in fact
demonstrate acceptable validity for identifying cancer
diagnoses and treatment patterns [6-13]. Unfortunately,
the lack of cancer stage data in Medicare claims remains
a major limiting factor in maximizing the utility of these
datasets for retrospective, outcomes-based research in
cancer patients[14,15]. In particular, cancer stage is a
crucial predictor of disease outcome and a key factor in
determining the appropriateness of treatment. For
example, in breast cancer patients, stage is associated
with overall and disease-free survival and, furthermore,
stage influences treatment decisions such as selection
and timing of surgery, radiotherapy, and chemotherapy
[16]. Epidemiologic studies of cancer patients typically
employ stage variables as covariates or as inclusion and
exclusion criteria, and thus it is essential to develop
accurate algorithms to account for cancer stage in stu-
dies using claims data.
Surprisingly, the need to derive such algorithms has
largely been ignored in the literature. Only one prior
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stage in breast cancer patients. Cooper et al. used the
Surveillance Epidemiology and End Results (SEER)-Med-
icare database, and authors reported that their claims-
based, single-predictor models were insufficient for
identifying patients with local, regional, and distant
stage disease. Sensitivity of these models for distinguish-
ing local from regional and distant disease was low–for
example, in breast cancer patient samples, only approxi-
mately 60%[17]. In the decade since the prior algorithm
was derived, no other algorithm has been presented in
the literature attempting to improve cancer stage classi-
fication using claims data. Thus studies have continued
to apply the algorithm by Cooper and colleagues to
derive cancer stage variables, despite the recognized lim-
itations of this algorithm [18,19] and the introduction of
measurement errors into such analyses.
Accordingly, we sought to derive an expanded predic-
tive algorithm based on multivariate modeling and to
improve the sensitivity and specificity for identifying
cancer stage, using our study sample of breast cancer
patients as an illustrative case. Using available Medicare
claims for breast cancer patients found in the SEER-
Medicare database, we developed a prediction algorithm
to identify patients with distant (stage IV) disease at
diagnosis and, among patients without distant disease, a
prediction algorithm to classify the extent of locoregio-
nal (stages I-III) disease.
Methods
Algorithm
Study sample
The SEER-Medicare database is comprised of a popula-
tion-based cohort of Medicare beneficiaries with incident
cancer identified through SEER registries, which account
for up to 26% of the United States’ population [20,21].
Our initial study population consisted of 150,764 women
(age ≥ 65 years) diagnosed with breast cancer between
1992 and 2002 identified through SEER-Medicare. From
this population, we excluded 5,217 patients with
unknown SEER historic stage (as this variable indicated
the presence or absence of metastases), and 19,816 with
in situ disease (as we intended to focus only on invasive
disease). We further excluded 47,114 patients who did
not have continuous Medicare Fee-for-Service coverage
or had any HMO coverage from 12 months prior to 9
months after their diagnosis date (as claims information
might be incomplete during these periods), and the 308
patients age <66, since these patients potentially would
not have had comprehensive claims information to define
the independent predictor covariates. We finally excluded
1,003 patients who died or were lost to follow-up within
9 months of their diagnosis date. This yielded a final
sample size of 77,306 patients in our study.
Dependent variable: Cancer stage
The “gold standard” for identifying cancer stage at diag-
nosis was determined using a combination of tumor vari-
ables available through SEER. Distant disease was
determined using the American Joint Committee on
Cancer (AJCC) [22] historic stage as reported to SEER,
which indicates tumor present in any distant site at can-
cer diagnosis (compared with tumor limited only to local
or regional sites at diagnosis). For our analysis, patients
with any distant disease were considered stage IV.
Patients without distant (stage IV) disease had local or
regional AJCC historic stage. T and N classification in
these patients were assigned based on SEER variables
for tumor size and extent of disease. Tumor size and
extent were categorized as ≤ 2 cm (T1); >2 to 5 cm
(T2); >5 cm (T3); or invading into the chest wall, ribs,
intercostals or serratus anterior muscles, extensive inva-
sion into the skin, inflammatory carcinoma, or further
contiguous extension into the skin (T4). Nodal disease
was categorized as 0 positive lymph nodes (N0); 1-3
positive lymph nodes (N1); 4-9 positive lymph nodes
(N2); or 10 or more positive lymph nodes (N3)[21]. Due
to the extent of missing data in the SEER database, loca-
tion of positive lymph nodes was not included in N clas-
sification. Stage I included T1N0 disease, stage II
included T0N1, T1N1, T2N0, T2N1, and T3N0 disease,
and stage III included T0-2N2, T3N1-2, T4N0-2, and
T0-4N3 disease. These classifications are based on
AJCC 2003 staging criteria[22].
Independent predictors
Candidate independent predictors were selected a priori
based on statistical significance in bivariate analyses (P <
0.25) and clinical significance in prior studies of cancer
patients[20,23-28]. Variables were defined by searching
through inpatient, outpatient, and carrier Medicare
claims or the denominator file for SEER-Medicare
linked data for demographic variables. A comprehensive
list of International Classification of Diseases, Ninth
Revision (ICD-9), Common Procedural Terminology
(CPT), and Revenue Center codes for each predictor are
listed in Table S1, Additional file 1.
Statistical analysis
All statistical analyses were conducted using SAS ver-
sion 9.1.3 (SAS Institute Inc, Cary, NC), and all statisti-
cal tests assumed a 2-tailed a of 0.05. The University of
Texas M. D. Anderson Cancer Center institutional
review board deemed this study exempt from review,
since the data were without identifiers.
We derived two separate logistic models and imple-
mented the models sequentially. The first model tested
the associations between predictor covariates and the
dichotomous outcome of stage IV versus non-stage IV
disease. Among the subset of patients who were not
categorized as having stage IV disease, the second
Smith et al. Epidemiologic Perspectives Innovations 2010, 7:1
http://www.epi-perspectives.com/content/7/1/1
Page 2 of 9model tested the associations between predictor covari-
ates (excluding the covariate for metastatic disease at
diagnosis) and the dichotomous outcome of stage I/II
(early) versus stage III disease. Outcomes were dichoto-
mized based on clinical rationale, given that treatment
of metastatic disease is palliative; and that treatment of
early stage disease is distinct in that breast conserving
therapy is a treatment option.
We used a split sample approach to develop and vali-
date our logistic models. Each model was derived from
the “training set,” selected using simple random sam-
pling without replacement (38,653 of 77,306 patients).
Parsimonious models were then selected based on statis-
tical significance (P < 0.25), clinical significance of cov-
ariates in prior studies,[20,23-28] and goodness-of-fit.
Prior studies were used as an initial guide for the selec-
tion of covariates to consider. The significance cutoff (P
< 0.25) was used to rule in covariates to keep. Examin-
ing the goodness-of-fit of the overall model was used to
rule out covariates to exclude. In combination, these
three criteria were used to select the final model.
Testing
Patients not included in the training set constituted the
“validation set”. In the validation set, the parameter asso-
ciated with each covariate estimated from the derivation
set was applied to each patient in the validation set to cal-
culate each patient’s predictive probability (calculated
probability = exp( )
exp( )
 
 
 
 
01 1 2 2
01 2 2 2 1

  
xx
xx
ii
ii

 )
of having stage IV disease in the first model and stage I/II
or stage III disease in the second model. Test characteris-
tics were calculated for probability cutpoints between 0.05
and 0.90, using two-by-two tables. The “gold standard” for
stage was considered the SEER stage; the test stage was
based on the calculated probability (for example, for a
probability cutpoint of 0.05, patients were predicted to
have stage I/II disease if their calculated probability was ≥
0.05, and not to have stage I/II disease if their calculated
probability was <0.05).
Combining equations
The prediction equations were then applied to isolate a
sample of patients with early stage disease. Specifically,
the two prediction equations were applied sequentially
to the validation sample in order to identify a subset of
patients with stage I/II dise a s e .T h ef i r s ts t e pu s e da
probability cutpoint of 0.05 to exclude patients with pre-
dicted stage IV disease. The second step was applied to
the subset identified in the first step and used a prob-
ability cutpoint of 0.90 to include patients with pre-
dicted stage I/II disease. These cutpoints were chosen
based on their test characteristics (high sensitivity, speci-
ficity, and positive predictive value [PPV] or negative
predictive value [NPV]). Finally, we also compared the
test characteristics derived from our multivariate predic-
tion equations to test characteristics derived from
single-predictor equations for distant and regional dis-
ease used in a prior study,[17] to determine whether
multivariate equations improved test characteristics
compared with the single-predictor equations.
Implementation
Example in Practice: Medicare test sample
Finally, we present an example that applies the predic-
tion equation. We used a test sample based on a claims-
only dataset, the national Medicare dataset. The national
Medicare dataset includes claims data for all Medicare
beneficiaries in the United States. Files contain data col-
lected by Medicare for reimbursement of health care
services for each beneficiary and include institutional
(inpatient and outpatient) and non-institutional (physi-
cians or other providers) final action claims [29]. We
initially included 127,607 women (age ≥ 65) with a diag-
nosis claim indicating invasive breast cancer in 2003
(International Classification of Diseases, Ninth Revision
(ICD-9) diagnosis code of 174) who underwent a breast-
cancer related procedure. We then excluded 23,715
patients who did not have at least 2 claims (on different
dates) specifying a diagnosis of invasive breast cancer
between January 1, 2003 and December 31, 2004 (at
least 1 claim must have occurred during 2003); 16,471
patients who had a breast cancer-related diagnosis or
procedure claim between January 1, 2002, and Decem-
ber 31, 2002; 5,719 patients who were receiving Medi-
care coverage because of end-stage renal disease or
disability; and 6,612 patients who lacked Part A or B
coverage or who had intermittent health maintenance
organization coverage in the 9 months after or in the 1
year before their breast cancer diagnosis date (of these
patients, 3,561 had incomplete information in the year
prior to diagnosis because they were <66 years of age);
for a total sample size of 56,725 patients. This method
for sample selection of incident breast cancer has been
validated in a prior study [30].
In this test sample, we appli e do u rd e r i v e da l g o r i t h m
and calculated the frequency of patients classified as
predicted stage IV and predicted stage I/II disease.
Again, for this sample, the first step used a probability
cutpoint of 0.05 and the second step a probability cut-
point of 0.90. As a test of our algorithm for consistency,
we compared the predicted frequencies to the actual
stage distribution in two populations: 1) the SEER-Medi-
care population (age >65 years) and 2) the National
Cancer Data Base population (age ≥ 70 years) [31].
Results
Patient characteristics
In 77,306 women, mean age was 76 years (standard
deviation 7 years), and 94% were white. Fifty-one per-
cent were stage I (39,147), 26% stage II (19,967), 11%
stage III (8,174), 4% stage IV (3,220) and 9% with non-
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(6,798). Forty-five percent were treated with breast con-
serving surgery, 49% with mastectomy, 44% with radio-
therapy, and 18% with chemotherapy (Table 1).
Prediction algorithm equations and test characteristics for
probability cutpoints
Candidate covariates tested in prediction equations are
listed in Table S1, Additional file 1. Parameter estimates
for the covariates included in each final prediction equa-
tion are listed in Table S2, Additional file 1.
Stage IV
Fourteen percent of all patients and 73% of patients with
stage IV disease had a claims code indicating possible
metastatic disease. Accordingly, the single-predictor
model including only this covariate had sensitivity of
73%; specificity 89%; PPV 22%; and NPV 99% for identi-
fying stage IV disease. After including covariates (Table
S2, Additional file 1) in the multivariate model, the sen-
sitivity was 81% (95% Confidence Interval 80% - 84%)
for identifying stage IV disease at a probability cutpoint
of 0.05. At this cutpoint, specificity was 89% (86% -
89%); PPV 24%; (22% - 25%) and NPV 99% (99% - 99%),
yielding a c-statistic of 0.93. (Table S3, Additional file 1)
The distribution of calculated predicted probabilities in
the validation set for patients with stage IV versus stage
I-III disease is presented in Figure 1a.
Stages I-III
In patients with stages I-III disease, 19% had a claims
code indicating axillary lymph node involvement. Speci-
fically, 2% of patients with stage I disease, 36% with
stage II disease, and 64% of patients with stage III dis-
ease had this claims code. The single-predictor model
including only this covariate yielded sensitivity of 87%
(specificity 61%; PPV 94%; NPV 39%) for identifying
stage I/II disease and sensitivity of 61% (and specificity
87%; PPV 39%; NPV 94%) for identifying stage III dis-
ease. After including covariates (Table S2, Additional
file 1) in the multivariate model, the sensitivity was 91%
(90% - 92%) for identifying stage I/II disease at a prob-
ability cutpoint of 0.80; and 83% (83% - 85%) at a cut-
point of 0.90. At a cutpoint of 0.90, specificity was 78%
(75% - 79%); PPV 98% (97% - 98%); and NPV 31% (30%
- 34%). For identifying stage III disease, the sensitivity
was 78% (75% - 79%) at a cutpoint of 0.10. At this cut-
point, specificity was 83% (83% - 85%); PPV 30% (30% -
34%); and NPV 98% (97% - 98%) (Table S3, Additional
file 1). These models yielded a c-statistic of 0.88. The
distribution of calculated predicted probabilities in the
validation set for patients with stage I/II versus stage III
disease is presented in Figure 1b.
Comparison with other single predictors
For comparison’s sake, for identifying stage IV disease,
the second most important predictor was axillary lymph
node dissection. This predictor alone would yield the
following test characteristics: sensitivity 67%; specificity
74%; PPV 10%; and NPV 98%. For identifying stage I/II
disease, the second most important predictor was breast
conserving surgery vs. mastectomy, yielding the follow-
ing test characteristics: sensitivity 49%; specificity 82%;
PPV 95%; and NPV 18%.
Combining equations
The prediction equations were most accurate for isolat-
ing patients with early stage disease. Specifically, after
applying the two prediction equations sequentially to
the validation sample to identify patients with predicted
stage I/II disease, a subset of 23,285 patients were
selected (of 38,653 patients, 36,417 were predicted to
Table 1 Study Sample Patient Characteristics, N = 77,306
Predictor Variable % of All Patients
Demographic
Age, mean (SD) 76 (7)
White race 94
Stage
Stage I 51
Stage II 26
Stage III 10
Stage IV 4
Stages I-III but T or N unknown 9
Extent of disease
a
Axillary LN involvement 19
Metastatic disease 14
Cancer treatment
a
No. visits to surgeon, mean (SD) 4 (3)
No. visits to medical oncologist, mean (SD) 4 (9)
No. visits to radiation oncologist, mean (SD) 3 (5)
Imaging (CT, MRI, PET, or bone scan) 25
Radiation therapy 44
Breast conserving surgery 45
Mastectomy 49
Axillary LN dissection 72
Chemotherapy (any agent) 18
Doxorubicin 7
Paclitaxel 3
No. physician visits, mean (SD) 14 (12)
Screening mammography 78
Influenza vaccine 34
General health status
a
No. hospital admission for any cause, mean (SD) 1 (1)
Charlson comorbidity score
0 comorbid conditions 69
1 comorbid condition 18
2 or more comorbid conditions 8
Unknown 5
Abbreviations: CT computed tomography; LN lymph nodes; MRI magnetic
resonance imaging PET positron emission tomography; SD standard deviation
a As indicated by Medicare claims codes; thus percentage of patients with
code for metastatic disease not equal to patients with Stage IV disease.
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Figure 1 Distribution of calculated probabilities (%) for patients with predicted stages I-III and stage IV disease (a). Distribution of
calculated probabilities for patients with predicted stages I-II and stage III disease (b). A calculated probability of 5% corresponds to a cutpoint
of 0.05. The histograms are normalized to 100%.
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were predicted to have stage I/II disease). The predictive
sample actually consisted of 98% gold standard stage I/II
disease (22,706 of 23,285), 2% stage III disease (549 of
23,285), and <1% stage IV disease (110 of 23,285). Of all
patients with gold standard stage I/II disease (29,546 of
38,653 validation patients), 23% (6,840 of 29,546) were
excluded (classified as other than stage I/II) as a result
of the algorithm (4,604 from the first model and 2,236
from the second model). (Figure 2, Figure 3).
Example in Practice: Medicare test sample and
comparison for consistency
In our Medicare test sample, after the first predictor
equation was applied, a total of 4% (2,333 of 56,725) of
women were predicted as having stage IV disease. This
compared favorably with the SEER-Medicare population,
which included 4% (3,220 of 77,306) of women with
confirmed stage IV disease; as well as the NCDB popu-
lation, which included 5% (1,913 of 41,071) confirmed
stage IV disease. After the second predictor equation
was applied to the remainder of the test sample, a total
of 79% (43,169 of 54,392) of women were predicted as
having stage I/II disease. This compared favorably with
the SEER-Medicare population, which included 80%
(59,114 of 74,086) of women with confirmed Stage I/II
disease; as well as the NCDB population, which included
84% (33,036 of 39,158) confirmed Stage I/II disease.
Discussion
In this cohort of older breast cancer patients, Medicare
claims data assisted the prediction of cancer stage.
Predictor equations using claims data alone were able to
achieve approximately 80% sensitivity and specificity for
identifying stage IV diseasea sw e l la sd i s t i n g u i s h i n g
stage I/II from stage III disease. Prediction models maxi-
mized NPV when distinguishing stage IV from stage I-
III disease but maximized PPV when distinguishing
stage I/II from III disease. With a resulting tradeoff of
lower PPV in the first model and lower NPV in the sec-
ond model, the algorithm was therefore found to be
best suited to most accurately identify early stage dis-
ease. Specifically, an algorithm combining the two equa-
tions seeking to identify patients with early stage disease
w a sa b l et oa c h i e v eas a m p l ei nw h i c h9 8 %o fp a t i e n t s
had stage I or II disease.
Our prediction models represent an improvement over
the single other previously published model. In this
prior study, Cooper et al. used single-predictor equa-
tions to identify cancer stage. To identify patients with
distant disease, authors tested a single variable based on
claims codes for metastatic disease. This single-predictor
model demonstrated 60% sensitivity and 58% PPV. To
distinguish patients with local versus regional disease,
authors tested a single variable based on the claim code
for axillary lymph node involvement. This single-predic-
tor model demonstrated 62% sensitivity and 85% PPV
[17]. The relatively poor test characteristics from this
prior study demonstrated that these single-predictor
models would be insufficient for predicting stage in
patients with breast cancer and suggested that claims
data alone would be inadequate for epidemiologic stu-
dies of cancer patients.
Figure 2 Receiver Operating Curve (ROC) for equation to predict stage IV disease.
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upon these test characteristics. Our single predictor
model demonstrated improvement, likely in part due to
a more extensive list of claims codes, with multiple cov-
ariates providing added value. Moreover, our algorithm
demonstrated consistency when results were compared
with population-based data from SEER-Medicare and
the NCDB. There are two important future research
applications of our prediction models. First, our multi-
variate logistic modeling method for developing a stage
predictor algorithm may similarly be applied to test
models and potentially develop stage prediction equa-
tions for patients diagnosed with cancers of other sites.
Second, our prediction equations may also be applied
directly to claims-based databases of breast cancer
patients who have unknown stage. Using a combination
of multiple predictors along with claims codes for meta-
static disease and axillary lymph node dissection, para-
meter estimates and calculated probabilities can be
applied to the prediction of patient breast cancer stage.
Our algorithm can therefore serve as a tool to assist in
the investigation of a variety of epidemiologic research
questions in breast cancer patients by allowing a sample
selection of those patients with early stage disease. In
addition, predicted early stage disease can be applied as
a covariate. Accordingly, since disease stage may be bet-
ter accounted for, claims databases of breast cancer
patients may also be better applied to address such
questions as the assessment of treatment utilization,
geographic variation, or outcomes in patients diagnosed
with early stage breast cancer. Specifically, for the stage
IV prediction model, a probability cutpoint between ≥
0.05 and ≥ 0 . 1 0w o u l db eh i g h l ys p e c i f i ca n ds e n s i t i v e
for identifying patients with stage IV disease. For the
stage I/II prediction model, a cutpoint between ≥ 0.80
and ≥ 0.90 would be highly specific and sensitive for dis-
tinguishing patients with stage I/II disease from patients
with stage III disease.
For the identification of patients with stage IV disease,
a selected probability cutpoint criterion could be trans-
lated into a dichotomous variable, and used either to
select a sample of patients with stage IV disease or used
in a “rule out” context, as an exclusion criterion. The
high NPV in our proposed model suggests that when
using these cutpoints to identify a sample limited to
patients with stage I-III disease, the likelihood of mis-
classification bias (bias due to the inappropriate inclu-
sion of patients with stage IV disease in the sample)
would be low in a “rule-out” setting.
For distinguishing patients with stage I/II versus III dis-
ease, the probability cutpoint criterion, translated into a
dichotomous variable, could be useful in various contexts,
such as excluding patients with stage III disease in order
to refine a study population of patients with early stage
breast cancer, or creating a dichotomous covariate to
adjust for potential confounding associated with stage I-III
disease. The test characteristics in our analysis suggest
that the combination of these prediction equations may be
particularly useful in the context of identifying breast can-
cer patients with early stage (stage I and II) disease.
Our study has limitations to consider. First, our cohort
was limited only to older patients with breast cancer.
Although the variables associated with stage are likely to
be similar in younger patients, exact parameter estimates
may differ, and the application of these models in
younger patients requires further validation. Additionally,
Figure 3 Receiver Operating Curve (ROC) for equation to predict stage I-III disease.
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claims, these models will also require validation in other
claims based data. If not all the proposed variables in our
models are available, however, at a minimum, adjustment
in multivariate analysis fora sm a n yp o s s i b l ea v a i l a b l e
candidate predictors proposed in our study could be use-
ful to improve modeling of breast cancer outcomes in
future studies. Although we excluded from our parsimo-
nious model covariates that required long-term follow-up
(specifically, overall survival and mastectomy 9 or more
months after diagnosis), our models still required both
retrospective and prospective data for up to 1 year prior
to and 1 year after the date of diagnosis. Thus, studies
applying our models would be limited to patients with
continuous coverage and complete claims information
over this time period. The gold standard for our out-
come, cancer stage, was based on pathologic variables in
SEER-Medicare, though given a lack of central pathology
review by the SEER program, unmeasured error may
have affected the gold standard, yielding potentially less
than 100% accuracy. Finally, if a sample was selected
based on the algorithm, sample characteristics derived
from algorithm predictor variables (for example, che-
motherapy, radiotherapy, and surgery utilization) may be
under- or overestimated compared with the complete
patient population, depending on the direction and sig-
nificance of their association with disease stage in the
prediction equations.
Conclusions
Medicare claims data can be utilized to derive a useful
algorithm to predict stage in breast cancer patients. In
particular, the predicted probability of early stage disease
can be easily generated when applying the prediction
algorithm to this patient population, thus substantially
improving the utility of Medicare claims data for study-
ing breast cancer.
Additional file 1: Table S1. Candidate Covariates and Claims Codes.
Table S2. Prediction Equations. Parameter estimates for stage IV versus
stages I-III disease and for stage. I/II versus stage III disease. Table S3. Test
Characteristics After Applying Prediction Equations on Validation Set
Samples.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-5573-7-1-
S1.DOC]
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